A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
Public ClinicalTrials.gov record NCT03424005. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase Ib/II, Open-label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic Breast Cancer (Morpheus-panBC)
Study identification
- NCT ID
- NCT03424005
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Enrollment
- 792 participants
Conditions and interventions
Conditions
Interventions
- Abemaciclib Drug
- Atezolizumab Drug
- Atirmociclib Drug
- Bevacizumab Drug
- Capecitabine Drug
- Chemotherapy (Gemcitabine + Carboplatin or Eribulin) Drug
- Empagliflozin Drug
- Fulvestrant Drug
- Inavolisib Drug
- Inavolisib (Dose #1) Drug
- Inavolisib (Dose #2) Drug
- Ipatasertib Drug
- Letrozole Drug
- Metformin Drug
- Nab-Paclitaxel Drug
- Palbociclib Drug
- Ribociclib (Dose #1) Drug
- Ribociclib (Dose #2) Drug
- SGN-LIV1A Drug
- Sacituzumab Govitecan Drug
- Selicrelumab Drug
- Tocilizumab Drug
- Trastuzumab Deruxtecan Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 29, 2018
- Primary completion
- Sep 29, 2030
- Completion
- Sep 29, 2030
- Last update posted
- Mar 15, 2026
2018 – 2030
United States locations
- U.S. sites
- 16
- U.S. states
- 8
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| City of Hope | Duarte | California | 91010 | Completed |
| University of California San Diego Medical Center | La Jolla | California | 92093 | Completed |
| Stanford Cancer Institute | Stanford | California | 94305 | Withdrawn |
| Rocky Mountain Cancer Center - Longmont | Longmont | Colorado | 80501 | Completed |
| H. Lee Moffitt Cancer Center and Research Inst. | Tampa | Florida | 33612 | Completed |
| Hackensack Univ Medical Center | Hackensack | New Jersey | 07601 | Withdrawn |
| Regional Cancer Care Associates, LLC | Howell Township | New Jersey | 07731 | Withdrawn |
| Rutgers Cancer Institute of New Jersey | New Brunswick | New Jersey | 08901 | Withdrawn |
| NYU Langone Medical Center | New York | New York | 10016 | Withdrawn |
| Thomas Jefferson University Hospital | Philadelphia | Pennsylvania | 19107 | Withdrawn |
| University of Pittsburgh Medical Center | Pittsburgh | Pennsylvania | 15213 | Withdrawn |
| Tennessee Oncology - Chattanooga Oncology & Hematology Associates | Chattanooga | Tennessee | 37404 | Recruiting |
| The West Clinic | Germantown | Tennessee | 38138 | Recruiting |
| Tennessee Oncology PLLC | Nashville | Tennessee | 37203 | Recruiting |
| Vanderbilt University Medical Center | Nashville | Tennessee | 37212 | Recruiting |
| Texas Oncology-Plano East | Plano | Texas | 75075-7787 | Withdrawn |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 29 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03424005, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 15, 2026 · Synced May 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03424005 live on ClinicalTrials.gov.